Ovid asks USPTO to review Marinus' patent around treatment of serious seizure condition
27 Mar 2024
Phase 3
Ovid Therapeutics is ramping up its patent fight with Marinus Pharmaceuticals.
The rival biotechs have been battling for more than a year over patent claims covering treatment methods for epileptic disorders, including a difficult-to-treat condition characterized by long-lasting seizures called status epilepticus (SE). On Tuesday, Ovid filed a new petition urging the US Patent and Trademark Office (USPTO) to review Marinus’ Patent No. 11,110,100, which covers methods for administering Marinus’ Phase 3 candidate ganaxolone to treat SE.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.